Total Payments
$106,982
2024 Payments
$28,467
Companies
2
Transactions
9

Payment Breakdown by Category

Research$104,982 (98.1%)
Other$2,000 (1.9%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $104,982 8 98.1%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 1.9%

Payments by Type

Research
$104,982
8 transactions
General
$2,000
1 transactions

Top Paying Companies

Company Total Records Latest Year
Octapharma USA, Inc. $104,982 8 $0 (2024)
PFIZER INC. $2,000 1 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $28,467 3 Octapharma USA, Inc. ($28,467)
2023 $76,514 5 Octapharma USA, Inc. ($76,514)
2022 $2,000 1 PFIZER INC. ($2,000)

All Payment Transactions

9 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/30/2024 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $997.00 Research
Study: NGAM-13 • Category: IMMUNOLOGY
12/30/2024 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $558.50 Research
Study: NGAM-13 • Category: IMMUNOLOGY
12/09/2024 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $26,911.80 Research
Study: NGAM-13 • Category: IMMUNOLOGY
06/30/2023 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $2,404.35 Research
Study: NGAM-13 • Category: IMMUNOLOGY
04/13/2023 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $1,394.59 Research
Study: NGAM-13 • Category: IMMUNOLOGY
04/13/2023 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $1,200.00 Research
Study: NGAM-13 • Category: IMMUNOLOGY
03/31/2023 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $23,457.15 Research
Study: NGAM-13 • Category: IMMUNOLOGY
02/10/2023 Octapharma USA, Inc. PANZYGA (Biological) Cash or cash equivalent $48,058.30 Research
Study: NGAM-13 • Category: IMMUNOLOGY
06/03/2022 PFIZER INC. OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,000.00 General
Category: IMMUNOLOGY

Research Studies & Clinical Trials

Study Name Company Amount Records
NGAM-13 Octapharma USA, Inc. $104,982 8

About Dr. Kyle Williams, M.D

Dr. Kyle Williams, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1598925182.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kyle Williams, M.D has received a total of $106,982 in payments from pharmaceutical and medical device companies, with $28,467 received in 2024. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "" ($104,982).

Practice Information

Products in Payments

  • PANZYGA (Biological) $104,982
  • OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) $2,000

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Boston